152 PART THREE | DELIRIUM 18. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008-16. 19. Tanase DM, Gosav EM, Radu S et al. The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity. Int J Mol Sci 2019;20:5238. 20. Holditch SJ, Brown CN, Lombardi AM et al. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatininduced acute kidney injury. Int J Mol Sci 2019;20:3011. 21. Basu RK, Wong HR, Krawczeski CD et al. Combining functional and tubular damage biomarkers improves diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol 2014;64:275362. 22. Katagiri D, Doi K, Matsubara T et al. New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care 2013;28:564-70. 23. Katagiri D, Doi K, Honda K et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg 2012;93:577-83. 24. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994-1007. 25. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology and prevention/therapy. Semin Nephrol 2010;30:570-81. 26. https://www.uptodate.com/contents/ cisplatin-nephrotoxicity (6 March 2021, date last accessed). 27. Dobyan DC, Levi J, Jacobs C et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980;213:551-56. 28. Sobrero A, Guglielmi A, Aschele C, Rosso R. Current strategies to reduce cisplatin toxicity. J Chemother 1990;2:3-7. 29. de Jongh FE, van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003;88:1199-1206. 30. Wan SH, Slusser JP, Hodge DO, Chen HH. The vascular-renal connection in patients hospitalized with hypertensive crisis: a population-based study. Mayo Clin Proc Innov Qual Outcomes 2018;2:148-54. 31. Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 1997;5:307-13 32. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:174652. 33. Ihbe-Heffinger A, Ehlken B, Bernard R et al. The impact of delayed chemotherapyinduced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36. 34. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8. 35. Himmelfarb J, Joannidis M, Molitoris B et al. Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol 2008;3:962-7. 36. Crona DJ, Faso A, Nishijima TF et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017;22:609-19.
RkJQdWJsaXNoZXIy MjY0ODMw